AD-223
- Generic Name
- AD-223
A Study to Evaluate the Efficacy and Safety of AD-223
Phase 3
Completed
- Conditions
- Hypertension,Essential
- Interventions
- Drug: AD-223B PlaceboDrug: AD-223A PlaceboDrug: AD-223C Placebo
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 502
- Registration Number
- NCT06052748
- Locations
- 🇰🇷
Hanyang University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath